Assessing Drug Release from Manipulated Abuse Deterrent Formulations

被引:10
|
作者
Feng, Xin [1 ]
Zidan, Ahmed [1 ]
Kamal, Nahid S. [1 ]
Xu, Xiaoming [1 ]
Sun, Dajun [2 ]
Walenga, Ross [2 ]
Boyce, Heather [2 ]
Cruz, Celia N. [1 ]
Ashraf, Muhammad [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Off Pharmaceut Qual, Off Testing & Res,Div Prod Qual Res, Silver Spring, MD 20993 USA
[2] US FDA, Ctr Drug Evaluat & Res, Off Gener Drugs, Off Res & Stand,Div Quantitat Methods & Modeling, Silver Spring, MD 20993 USA
关键词
dissolution; abuse-deterrent formulation; USP Apparatus 4; manipulation; powder dissolution; opioid abuse; WATER-SOLUBLE DRUG; IN-VITRO PERFORMANCE; POLYETHYLENE OXIDE; DISSOLUTION RATE; MATRIX TABLETS; APPARATUS; IMPACT; BIOAVAILABILITY; ENHANCEMENT; DYNAMICS;
D O I
10.1208/s12249-019-1595-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is a need to develop in vitro dissolution methods that discriminate for particle size of the manipulated abuse deterrent formulation (ADF) and that can be used for in vivo predictive models since dissolution methods developed for intact formulation might not be suitable for manipulated ones. A vertical diffusion cell (VDC) and United States Pharmacopeia (USP) Apparatus 1, 2, and 4 were evaluated for measuring the dissolution of intact and manipulated metoprolol succinate tablets with abuse deterrent-like properties. These tablets were physically manipulated to produce fine (106-500 mu m) and coarse (500-1000 mu m) powder samples. The VDC method was not able to discriminate the effect of particle size on drug release with varied stirring rate (200 to 800 rpm), molecular weight cut-off (MWCO, 3-5 kDa to 12-14 kDa) of the diffusion membrane, or composition and ionic strength (0.45% and 0.9%) of receiver medium. Standard and modified USP Apparatus 1 and 2 methods were assessed; however, large variations (RSD>20%) were observed with USP Apparatus 1 for manipulated product dissolution and floating powder samples caused failure of auto-sampling when using standard USP Apparatus 2. For the USP Apparatus 4 dissolution method, packing configuration (1, 3, 8 layers and blend), ionic strength of dissolution medium (0.017, 0.077, and 0.154 M additional NaCl), and flow rate (4, 8, 16 mL/min) were studied to discriminate the effect of particle size on release. The USP Apparatus 4 dissolution method was optimized by using a packaging configuration of 8 layers with 8 mL/min flow rate which exhibited low variability and complete drug release and it could be used for in vivo predictive models. The dissolution method variables can be optimized for a specific product for desirable reproducibility and discriminatory power when using USP Apparatus 4.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Effects of Drug-Polymer Interactions on Tablet Properties During the Development of Abuse-Deterrent Dosage Forms
    Meruva, Saikishore
    Donovan, Maureen D.
    AAPS PHARMSCITECH, 2019, 20 (03)
  • [42] pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations
    Riis, Therese
    Bauer-Brandl, Annette
    Wagner, Torsten
    Kranz, Heiko
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 65 (01) : 78 - 84
  • [43] Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model
    Kumar, Varun M.
    Agboola, Foluso
    Synnott, Patricia G.
    Segel, Celia
    Webb, Maggie
    Ollendorf, Daniel A.
    Banken, Reiner
    Chapman, Richard H.
    VALUE IN HEALTH, 2019, 22 (04) : 416 - 422
  • [44] Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting
    Peacock, Amy
    Larance, Briony
    Bruno, Raimondo
    Pearson, Sallie-Anne
    Buckley, Nicholas A.
    Farrell, Michael
    Degenhardt, Louisa
    ADDICTION, 2019, 114 (03) : 389 - 399
  • [45] Physical Barrier Type Abuse-Deterrent Formulations: Mechanistic Understanding of Sintering-Induced Microstructural Changes in Polyethylene Oxide Placebo Tablets
    Boyce, Heather J.
    Dave, Vivek S.
    Scoggins, Myke
    Gurvich, Vadim J.
    Smith, Daniel T.
    Byrn, Stephen R.
    Hoag, Stephen W.
    AAPS PHARMSCITECH, 2020, 21 (03)
  • [46] Aversion liquid-filled drug releasing capsule (3D-RECAL): A novel technology for the development of immediate release abuse deterrent formulations using a fused deposition modelling (FDM) 3D printer
    Palekar, Siddhant
    Nukala, Pavan Kumar
    Patel, Ketan
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 621
  • [47] Physiological Considerations and In Vitro Strategies for Evaluating the Influence of Food on Drug Release from Extended-Release Formulations
    Koziolek, Mirko
    Kostewicz, Edmund
    Vertzoni, Maria
    AAPS PHARMSCITECH, 2018, 19 (07): : 2885 - 2897
  • [48] Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations
    Kranz, H
    Wagner, T
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2006, 62 (01) : 70 - 76
  • [49] Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine
    Rossiter, Louis F.
    Kwong, Winghan Jacqueline
    Marrett, Elizabeth
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 35 - 44
  • [50] POLYACRYLATE TERPOLYMER FOR PROLONGED DRUG-RELEASE TYPE FORMULATIONS
    RAK, J
    VITKOVA, M
    CHALABALA, M
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1993, 39 (03) : 117 - 119